165 results on '"Rannikko, Antti"'
Search Results
2. EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL).
3. EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL).
4. Phage Biosensor for the Classification of Metastatic Urological Cancers from Urine
5. Table S2 from Risk of Clinically Significant Prostate Cancer after a Nonsuspicious Prostate MRI—A Comparison with the General Population
6. Data from Risk of Clinically Significant Prostate Cancer after a Nonsuspicious Prostate MRI—A Comparison with the General Population
7. Data from Risk of Clinically Significant Prostate Cancer after a Nonsuspicious Prostate MRI—A Comparison with the General Population
8. Table S2 from Risk of Clinically Significant Prostate Cancer after a Nonsuspicious Prostate MRI—A Comparison with the General Population
9. Figure S1 from Risk of Clinically Significant Prostate Cancer after a Nonsuspicious Prostate MRI—A Comparison with the General Population
10. Table S1 from Risk of Clinically Significant Prostate Cancer after a Nonsuspicious Prostate MRI—A Comparison with the General Population
11. PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer
12. LONGITUDINAL CHANGES IN PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH HIGH-RISK BIOCHEMICALLY RECURRENT (BCR) NONMETASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) FROM THE EMBARK STUDY
13. Risk of Clinically Significant Prostate Cancer after a Nonsuspicious Prostate MRI—a Comparison with the General Population
14. Using unsupervised topic modeling to uncover document hierarchy and latent topics in prostate cancer clinical texts
15. MRI-Targeted Prostate Biopsy Introduces Grade Inflation and Overtreatment
16. Early detection of clinically significant prostate cancer: protocol summary and statistical analysis plan for the ProScreen randomised trial
17. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer
18. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
19. Histomic and transcriptomic features of MRI‐visible and invisible clinically significant prostate cancers are associated with prognosis
20. Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study
21. Capturing the Kidney Transcriptome by Urinary Extracellular Vesicles—From Pre-Analytical Obstacles to Biomarker Research
22. Improving Prostate Cancer Detection with Breast Histopathology Images
23. Capturing the Kidney Transcriptome by Urinary Extracellular Vesicles – from Preanalytical Obstacles to Biomarker Research
24. Protocol summary and statistical analysis plan for the randomized trial of early detection of clinically significant prostate cancer (ProScreen)
25. Prognostic impact of kallikrein‐related peptidase transcript levels in prostate cancer
26. Data from Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer
27. Supplementary Tables S1-S7, Figures S1-S4 from Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer
28. Supplementary Tables S1-S7, Figures S1-S4 from Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer
29. Abstract 2091: Open-source single-cell spatial image analysis pipeline for ten-plex immunofluorescence of histological prostate cancer tissue sections
30. Data from Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer
31. LBA02-09 EMBARK: A PHASE 3 RANDOMIZED STUDY OF ENZALUTAMIDE OR PLACEBO PLUS LEUPROLIDE ACETATE AND ENZALUTAMIDE MONOTHERAPY IN HIGH-RISK BIOCHEMICALLY RECURRENT PROSTATE CANCER
32. Genome-wide mRNA profiling in urinary extracellular vesicles reveals stress gene signature for diabetic kidney disease
33. Incidence of erectile dysfunction treatment after radical prostatectomy by Statin use in Finnish Nationwide Cohort Study
34. The roles of proteases in prostate cancer
35. PP2A methylesterase PME ‐1 suppresses anoikis and is associated with therapy relapse ofPTEN‐deficient prostate cancers
36. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer—Data from the International Multicenter Prospective PRIAS Study
37. Prospective Longitudinal Health-related Quality of Life Analysis of the Finnish Arm of the PRIAS Active Surveillance Cohort: 11 Years of Follow-up
38. Triggers for Intervention
39. Infectious complications after transrectal MRI-targeted and systematic prostate biopsy
40. Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression
41. Characteristics of Patients in SPCG-15—A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer
42. Abstract 2234: Incidence of clinically significant prostate cancer after negative prostate MRI - comparison to general population
43. Abstract 4134: Stromal FAP expression is associated with MRI visibility and patient survival in prostate cancer
44. Abstract 5171: Gene expression in multi-parametric MRI visible and invisible prostate cancers predicts progression
45. MP43-05 UPFRONT MRI IS THE NEW STANDARD, HAVE CONFIRMATORY BIOPSIES BECOME OBSOLETE?
46. MP43-14 EXTERNAL VALIDATION OF A MODEL PREDICTING INCREASE IN GLEASON GRADE FOR MEN ON ACTIVE SURVEILLANCE IN THE GAP3 CONSORTIUM DATABASE
47. AI Model for Prostate Biopsies Predicts Cancer Survival
48. Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol
49. Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer
50. Detecting disease associated biomarkers by luminescence modulating phages
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.